10:35am Tuesday 25 July 2017

Scientists uncover possible therapeutic targets for rare autism spectrum disorder

Headshot of Dr. Antonio Bedalov

Dr. Antonio Bedalov

Robert Hood / Fred Hutch News Service

SEATTLE – Jan. 30, 2017 – Researchers have uncovered 30 genes that could, one day, serve as therapeutic targets to reverse Rett syndrome, a rare neurological disorder that affects only girls and is a severe form of an autism spectrum disorder.

The study, led by scientists at Fred Hutchinson Cancer Research Center in Seattle, will be published January 30 in the Proceedings of the National Academy of Sciences.

There are currently no treatments specific to Rett syndrome, which affects approximately 15,000 girls and women in the U.S. and 350,000 around the world. Girls with Rett syndrome are born healthy and seem like any other baby up to one or two years of age. But then they start missing milestones and backslide in development.

“They have this period of normal development, and then it’s taken away from them,” said Dr. Antonio Bedalov, who led the study and is a clinical researcher at Fred Hutch. “It’s devastating for the families.”

The disorder is tied to a genetic defect in the MeCP2 gene, which is carried on the X chromosome. Girls, of course, have two copies of this chromosome but one X is silenced in every cell. Even though, on average, half of a girl’s cells will produce the healthy version of this X-linked gene, the mutation in the other half of cells is enough to trigger the symptoms of the disorder.

Using adult mouse cells in the lab, Bedalov and his colleagues identified a way to partially reawaken the “inactive X,” the X chromosome that is silenced in every cell. The researchers were also able to reactivate the normal copy of the MeCP2 gene.

Bedalov emphasized that the findings are still in the preclinical stage and that therapeutics are a long ways off.

But it’s a start, Bedalov said. Because their approach leads to the reactivation of the entire chromosome, it could also apply to other, similar disorders that involve the X chromosome.

The Rett Syndrome Research Trust funded the project.

# # #

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on FacebookTwitter or YouTube.

CONTACT
Molly McElroy
206.667.6651 (desk)
mwmcelro@fredhutch.org

 


Share on:
or:

Health news